Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation

This publication has 16 references indexed in Scilit:

• Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels
  Circulation, 1998
• C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy
  Journal of the American College of Cardiology, 1998
• Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial
  Circulation, 1998
• Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
  New England Journal of Medicine, 1997
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
  New England Journal of Medicine, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic Plaques
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
  The Lancet, 1994
• Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
  The American Journal of Cardiology, 1991
• The Lipid Research Clinics Coronary Primary Prevention Trial Results
  JAMA, 1984